Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05655208
Other study ID # LungCluster
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2010
Est. completion date November 30, 2019

Study information

Verified date March 2023
Source Paris Translational Research Center for Organ Transplantation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Lung transplantation is the only curative treatment for individuals with end-stage lung disease. Understanding the lung allograft's histological lesions, which is key for the patient management, remains difficult because of the multiplicity of lesions associated with graft outcome and their interpenetration. The goal of this observational study is to identify clusters of histological lesion on transbronchial biopsies in Lung transplant recipient prospective cohort. The main question[s] it aims to answer are: - what are the different pattern of histological lesion? - what are the graft outcome associated with the different clusters?


Description:

SCIENTIFIC JUSTIFICATION: With more than three million deaths per year, the chronic obstructive pulmonary disease is currently the third cause of mortality worldwide , and contributes to the growing number of individuals with end-stage lung disease, which is now a major issue for world public health. Overall, for individuals with end-stage lung disease, lung transplantation (LTx) is the only treatment able to increase patient survival and quality of life, with more than 4,500 lung transplantations performed each year. Despite major progresses made in the last decade regarding organ preservation, procurement and short term outcome little improvements have been made on the histological characterization of rejection, which remains the main determinant of patient death after lung transplantation. One of the main limitation of histological analysis is the multiplicity of lesions associated with graft outcome and their interpenetration. Historically, the perivascular infiltrate or cellular rejection (A lesions), and the lymphocytic bronchiolitis (B lesions) are the first histological lesions associated with graft dysfunction and stand as key parameters in patient management. In addition to A and B lesions, a wide spectrum of histological lesions of the lung allograft is associated with clinical outcomes. However, to our best knowledge, only few studies thoroughly investigated the various elementary lesions in the broad scope of histological analysis, and their association with clinical outcomes. Although informative, those studies usually suffer from a small number of patients, convenience clinical samples from registry, and the lack of innovative statistical approach. Overall, the wide spectrum of the allograft lesions has not been investigated using a large number of transbronchial biopsies with standardized protocol and biopsy reading, and a multidimensional approach on deeply phenotyped data. The recent use of unsupervised method in organ transplantation has permitted the identification of clinically relevant patient clusters and may be a relevant strategy to decipher the heterogeneity in histological lesions in lung recipients. Therefore, using a deeply phenotyped prospective cohort of lung recipients and consecutive transbronchial biopsies with protocolized evaluation and interpretation covering the different cases scenario encountered in clinical practice, the investigators aim to identify histological clusters based on histological lesions and assess their associations with graft and patient outcomes. OBJECTIVES: Main objective: To identify of histological cluster of lung allograft Transbronchial biopsies Secondary objective: To evaluate association of each cluster with baseline clinical data and anti HLA donor specific antibody and graft outcome INTERVENTIONS: This is an observational study that involves only minimal risk and constraints. The intervention consists in the evaluation of parameters measured as part of the standard of care at the time of post-transplant allograft biopsy. No medicinal product is under investigation in this protocol. EXPECTED BENEFITS for the participants and for society: There will be no immediate individual benefit for the patient to participate in the study. This study will provide us with data of Lung transplant patients that may allow the improvement of clinical decisions and the long-term lung allograft management. MINIMAL RISKS AND CONSTRAINTS added by the study No additional intervention beyond the standard of care will be performed in this study. RECRUITING CENTER: - Single center study - Hopital Foch, Suresnes, France


Recruitment information / eligibility

Status Completed
Enrollment 498
Est. completion date November 30, 2019
Est. primary completion date November 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - i) age greater than 18 years, - ii) single or bilateral lung transplantation, - iii) having at least one transbronchial biopsy available for analysis - iv) consent their clinical data to be used for research Exclusion Criteria: • Biopsies with at least one missing value in the standardized clinical report were excluded

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Paris Translational Research Center for Organ Transplantation Hopital Foch

Outcome

Type Measure Description Time frame Safety issue
Primary graft loss resulting in death or re-transplantation and all-cause mortality 118 months
Secondary chronic lung allograft dysfunction occurrence 118 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06309628 - Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
Withdrawn NCT02893176 - Macitentan in the Treatment of Organ Rejection After Lung Transplantation Phase 4
Completed NCT02441413 - Transplant Optimization Using Functional Imaging (TROFI) N/A
Recruiting NCT05375149 - Exhaled Breath Particles in Lung Transplantation
Active, not recruiting NCT03967340 - PREdiction of Chronic LUng Allograft Dysfunction
Active, not recruiting NCT05260372 - Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
Recruiting NCT06082037 - A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction Phase 3
Recruiting NCT04714801 - Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation Phase 1/Phase 2
Active, not recruiting NCT05170425 - LAMBDA 002 (Lung Registry) Study
Completed NCT02474927 - Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Phase 2
Recruiting NCT05006742 - Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients N/A
Recruiting NCT02812290 - Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
Not yet recruiting NCT03500575 - Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients N/A
Withdrawn NCT03805178 - Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization Phase 2
Completed NCT03359863 - Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction Phase 2
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3
Completed NCT01985412 - Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
Completed NCT04234919 - Longitudinal Study of Cell Free DNA in Lung Transplant
Recruiting NCT04837339 - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation N/A
Recruiting NCT03090581 - Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation. N/A